In addition to gene correction therapy and cell transplantation techniques, multidisciplinary
approaches to drug discovery and development offer promising therapeutic strategies for …

Muscular dystrophies are characterized by weakness and wasting of skeletal muscle
tissues. Several drugs targeting the myostatin pathway have been used in clinical trials to …

Gene-targeted therapies, such as adeno-associated viral vector (AAV)-mediated gene
therapy and cell-mediated therapy using myogenic stem cells, are hopeful molecular …

Myostatin is a negative regulator of muscle mass. Important advances in our understanding
of the complex biology of this factor have revealed the therapeutic potential of antagonizing …

In the past 20 years, myostatin, a negative regulator of muscle mass, has attracted attention
as a potential therapeutic target in muscular dystrophies and other conditions. Preclinical …

Skeletal muscle is the largest organ in the human body, and plays an important role in body
movement and metabolism. Skeletal muscle mass is lost in genetic disorders such as …

Genetic deletion of Myostatin, a member of the Transforming Growth Factor-beta family of
signalling molecules, resulted in excessive growth of skeletal muscle. It demonstrated the …

Mutations in myostatin (GDF8) cause marked increases in muscle mass, suggesting that this
transforming growth factor‐β (TGF‐β) superfamily member negatively regulates muscle …

The elusive promise of myostatin inhibition for muscular dys... : Current Opinion in Neurology
The elusive promise of myostatin inhibition for muscular dystrophy : Current Opinion in …

Increasing the size and strength of muscles represents a promising therapeutic strategy for
musculoskeletal disorders, and interest has focused on myostatin, a negative regulator of …